POSITIVEID (PSID) 10-Q 13 Aug 15 2015 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 07, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Entity Registrant Name	POSITIVEID Corp
Entity Central Index Key	1,347,022
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	PSID
Entity Common Stock, Shares Outstanding		350,097,044

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 672	$ 145
Prepaid expenses and other current assets	95	5
Total Current Assets	767	150
Property and Equipment, net	4	3
Goodwill	510	510
Intangibles, net	225	347
Other assets	11	11
Total Assets	1,517	1,021
Current Liabilities:
Accounts payable	73	127
Accrued expenses and other current liabilities	558	693
Deferred revenue	2,500	2,571
Tax contingency	345	480
Notes payable	510	676
Short-term convertible debt, net of discounts and premiums	1,202	1,527
Embedded conversion option liability	5,703	2,152
Total Current Liabilities	10,891	8,226
Long Term liabilities:
Mandatorily redeemable Series I preferred stock, 2,500 shares authorized; $0.001 par value; 1,625 and 1,000 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively; liquidation preference and redemption value of $1,713 and $1,065 at March 31, 2015 and December 31, 2014, respectively	2,102	1,241
Total Liabilities	$ 12,993	$ 9,467
Commitments and contingencies (Note 7)
Stockholders’ Deficit:
Convertible preferred stock, 5,000,000 shares authorized, $.001 par value; Series F Preferred - nil shares issued and outstanding at December 31, 2014 and June 30, 2015	$ 0	$ 0
Common stock, 1,970,000,000 shares authorized, $.01 par value; 319,010,900 and 169,531,322 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively	3,190	1,695
Additional paid-in capital	124,885	122,616
Accumulated deficit	(139,551)	(132,757)
Total Stockholders’ Deficit	(11,476)	(8,446)
Total Liabilities and Stockholders’ Deficit	$ 1,517	$ 1,021

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets [Parenthetical] - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Common Stock, Shares Authorized	1,970,000,000	1,970,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.01	$ 0.01
Common Stock, Shares, Issued	319,010,900	169,531,322
Common Stock, Shares, Outstanding	319,010,900	169,531,322
Series I Preferred Stock [Member]
Mandatorily Redeemable Preferred Stock Par Or Stated Value Per Share (in dollars per share)	$ 0.001	$ 0.001
Mandatorily Redeemable Preferred Stock Shares Authorized	2,500	2,500
Mandatorily Redeemable Preferred Stock, Shares Issued	1,625	1,000
Mandatorily Redeemable Preferred Stock, Shares Outstanding	1,625	1,000
Mandatorily Redeemable Preferred Stock, Liquidation Preference Value	$ 1,737	$ 1,065
Series F Preferred Stock [Member]
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenue	$ 51	$ 420	$ 182	$ 420
Operating expenses:
Direct labor	46	94	148	94
Selling, general and administrative	1,122	799	2,911	2,760
Research and development	243	64	539	86
Total operating expenses	1,411	957	3,598	2,940
Operating loss	(1,360)	(537)	(3,416)	(2,520)
Other income (expense):
Interest expense	(1,177)	(526)	(2,302)	(845)
Change in fair value of embedded conversion option liability	(481)	0	(1,177)	0
Loss on extinguishment of debt	(129)	0	(233)	0
Other income (expense), net	214	0	334	(7)
Total interest and other expense, net	(1,573)	(526)	(3,378)	(852)
Net loss	(2,933)	(1,063)	(6,794)	(3,372)
Preferred stock dividends	(24)	(25)	(47)	(52)
Beneficial conversion on preferred stock	0	(84)	0	(480)
Net loss attributable to common stockholders	$ (2,957)	$ (1,172)	$ (6,841)	$ (3,904)
Loss per common share attributable to common stockholders - basic and diluted (in dollars per share)	$ (0.01)	$ (0.02)	$ (0.03)	$ (0.06)
Weighted average shares outstanding - basic and diluted (in shares)	264,745	75,210	232,197	68,340

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Stockholders' Deficit - 6 months ended Jun. 30, 2015 - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2014	$ (8,446)	$ 1,695	$ 122,616	$ (132,757)
Balance (in Shares) at Dec. 31, 2014		169,532
Net loss	(6,794)	$ 0	0	(6,794)
Stock based compensation	369	$ 64	305	0
Stock based compensation (in shares)		6,400
Preferred stock dividends	(47)	$ 0	(47)	0
Common Stock issued pursuant to convertible note conversions	1,781	$ 1,431	350	0
Common Stock issued pursuant to convertible note conversions (in shares)		143,078
Reclassification of premium upon debt conversion and redemption	421	$ 0	421	0
Reclassification of derivative liability upon debt conversion	1,240	0	1,240	0
Balance at Jun. 30, 2015	$ (11,476)	$ 3,190	$ 124,885	$ (139,551)
Balance (in shares) at Jun. 30, 2015		319,010

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net loss	$ (6,794)	$ (3,372)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	125	161
Stock-based compensation	1,182	1,415
Convertible debt discounts and premium amortization	2,023	408
Loss on extinguishment of debt	233	0
Change in fair value of embedded conversion option liability	1,177	0
Gain on sale of investment shares	(319)	0
Allowance for collection of note receivable	110	0
Note issued as consideration for services	67	0
Changes in operating assets and liabilities:
Decrease in tax contingency	(134)	0
Increase in prepaid expenses and other current assets	(7)	(10)
Decrease in accounts payable and accrued expenses	(189)	(131)
Increase in accrued interest	279	410
Increase (decrease) in deferred revenue	(71)	81
Net cash used in operating activities	(2,318)	(1,038)
Cash flows from investing activities:
Proceeds from sale of investment shares, net	319	0
Cash loaned for note receivable	(110)	0
Purchase of property and equipment	(4)	(5)
Net cash (used in) provided by investing activities	205	(5)
Cash flows from financing activities:
Proceeds from issuances of Series F Preferred Stock, net of fees	0	100
Proceeds from debt financing, net of fees	3,197	961
Payments on short-term debt	(557)	0
Net cash provided by financing activities	2,640	1,061
Net (decrease) increase in cash and cash equivalents	527	18
Cash and cash equivalents, beginning of period	145	165
Cash and cash equivalents, end of period	672	183
Supplementary Cash Flow Information:
Cash paid for interest	35	0
Cash paid for income tax	0	0
Non-cash financing and investing activities:
Preferred dividends converted into common stock	0	20
Conversion of promissory notes into common stock	1,781	178
Beneficial conversion value recognized as dividend in Series F preferred stock conversions	0	480
Reclassification of embedded conversion option liability upon conversion of debt	1,240	0
Reclassification of stock settle debt premium to equity upon conversion of debt	421	0
Discounts recorded for loan fees and original issue discount	496	0
Embedded conversion option liability recorded as debt discount	$ 3,615	$ 0

Organization and Basis of Prese

Organization and Basis of Presentation	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description and Basis of Presentation [Text Block]	1. Organization and Basis of Presentation PositiveID Corporation, including its wholly owned subsidiary MicroFluidic Systems (“MFS”) (collectively, the “Company” or “PositiveID”), develops molecular diagnostic systems for bio-threat detection, for rapid diagnostic testing, and also develops assays to detect a range of biological threats. The Company’s M-BAND (Microfluidic Bio-agent Autonomous Networked Detector) system is an airborne bio-threat detection system developed for the homeland defense industry, to detect biological weapons of mass destruction. The Company is also developing the handheld automated pathogen detection system Firefly Dx for rapid diagnostics, both for point of need and clinical applications. PositiveID is a Delaware corporation formed in 2001. The Company commenced operations in 2002 as VeriChip Corporation. In 2007, the Company completed an initial public offering of its common stock. Authorized Common Stock On April 30, 2015, the Company filed the Sixth Amendment to the Second Amendment and Restated Certificate of Incorporation, as amended, with the State of Delaware to increase the number of authorized common shares to 1.97 1.97 Going Concern The Company’s unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. As of June 30, 2015, the Company had a working capital deficiency of approximately $ 10.1 139.6 8.1 132.8 6.8 2.3 We have incurred operating losses prior to and since the merger that created PositiveID. The current 2015 operating losses are the result of research and development expenditures and selling, general and administrative expenses related to our molecular diagnostics and detection products. We expect our operating losses to continue through 2015. These conditions raise substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern is dependent upon our ability to obtain financing to fund the continued development of our products and to support working capital requirements. Until we are able to achieve operating profits, we will continue to seek to access the capital markets. During the six months ended June 30, 2015, we raised approximately $ 2.6 The Company intends to continue to access capital to provide funds to meet its working capital requirements for the near-term future. In addition and if necessary, the Company could reduce and/or delay certain discretionary research, development and related activities and costs. However, there can be no assurances that the Company will be able to negotiate additional sources of equity or credit for its long term capital needs. The Company’s inability to have continuous access to such financing at reasonable costs could materially and adversely impact its financial condition, results of operations and cash flows, and result in significant dilution to the Company’s existing stockholders. The Company’s consolidated financial statements do not include any adjustments relating to recoverability of assets and classifications of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. Basis of Presentation The accompanying consolidated balance sheet as of December 31, 2014 has been derived from the Company’s audited financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2014. The accompanying unaudited condensed consolidated financial statements for the three and six months ended June 30, 2015 and 2014 have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities Exchange Commission (“SEC”). Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. In the opinion of the Company’s management, all adjustments (including normal recurring adjustments) necessary for a fair presentation for the periods presented have been reflected as required by Regulation S-X, Rule 10-01. The unaudited condensed consolidated statements of operations for the three and six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the entire year. These statements should be read in conjunction with the consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. New Accounting Pronouncements The Accounting Standards Updates during the six months ended June 30, 2015, including the pronouncements discussed below, are not expected to have a significant effect on the Company’s consolidated financial position or results of its operations. ASU 2014 – 09: In June 2014, FASB issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”. The update gives entities a single comprehensive model to use in reporting information about the amount and timing of revenue resulting from contracts to provide goods or services to customers. The proposed ASU, which would apply to any entity that enters into contracts to provide goods or services, would supersede the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification. Additionally, the update would supersede some cost guidance included in Subtopic 605-35, Revenue Recognition – Construction-Type and Production-Type Contracts. The update removes inconsistencies and weaknesses in revenue requirements and provides a more robust framework for addressing revenue issues and more useful information to users of financial statements through improved disclosure requirements. In addition, the update improves comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. The update is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. This updated guidance is not expected to have a material impact on our results of operations, cash flows or financial condition. ASU 2014-12: In June 2014, FASB issued Accounting Standards Update (“ASU”) No. 2014-12, “Compensation – Stock Compensation (Topic 718); Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period”. The amendments in this ASU apply to all reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718 as it relates to awards with performance conditions that affect vesting to account for such awards. For all entities, the amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The effective date is the same for both public business entities and all other entities. Entities may apply the amendments in this ASU either (a) prospectively to all awards granted or modified after the effective date or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. If retrospective transition is adopted, the cumulative effect of applying this Update as of the beginning of the earliest annual period presented in the financial statements should be recognized as an adjustment to the opening retained earnings balance at that date. Additionally, if retrospective transition is adopted, an entity may use hindsight in measuring and recognizing the compensation cost. This updated guidance is not expected to have a material impact on our results of operations, cash flows or financial condition. ASU 2014-15: In August 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40); Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. This update requires management of the Company to evaluate whether there is substantial doubt about the Company’s ability to continue as a going concern. This update is effective for the annual period ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company does not expect this standard to have an impact on the Company’s consolidated financial statements upon adoption. ASU 2015-03: In April 2015, the Financial Accounting Standards Board issued Accounting Standards Update No. 2015-03,"Simplifying the Presentation of Debt Issuance Costs," which changes the presentation of debt issuance costs in financial statements. Under this guidance such costs would be presented as a direct deduction from the related debt liability rather than as an asset. This guidance is effective for interim and annual reporting periods beginning after December 15, 2015. The Company does not expect this ASU to have a material impact on its consolidated financial statements. ASU 2015-08: On May 8, 2015, the FASB issued ASU 2015-08, “Business Combinations (Topic 805) Pushdown Accounting” which conforms the FASB’s guidance on pushdown accounting with the SEC’s guidance. ASU 2015-08 is effective for annual periods beginning after December 15, 2015. The Company does not expect this ASU to have a material impact on its consolidated financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries of which all are inactive except for MFS. All significant intercompany transactions have been eliminated in the consolidation. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates during the reported periods include allowance for doubtful accounts receivable, valuation of goodwill and intangible assets, valuation of derivatives, valuation of beneficial conversion features, estimate of the contingent earn-out liability, valuation of stock-based compensation and an estimate of the deferred tax asset valuation allowance. Intangible assets are carried at cost less accumulated amortization, computed using the straight-line method over the estimated useful lives. Customer contracts and relationships were previously being amortized over 3 5 2 The Company continually evaluates whether events or circumstances have occurred that indicate the remaining estimated useful lives of its definite-lived intangible assets may warrant revision or that the remaining balance of such assets may not be recoverable. The Company uses an estimate of the related undiscounted cash flows attributable to such asset over the remaining life of the asset in measuring whether the asset is recoverable. The Company records goodwill as the excess of the purchase price over the fair values assigned to the net assets acquired in business combinations. Goodwill is allocated to reporting units as of the acquisition date for the purpose of goodwill impairment testing. The Company’s reporting units are those businesses for which discrete financial information is available and upon which segment management makes operating decisions. Goodwill of a reporting unit is tested for impairment at year-end, or between testing dates if an impairment condition or event is determined to have occurred. In assessing potential impairment of the intangible assets recorded in connection with the MFS acquisition as of June 30, 2015, we considered the likelihood of future cash flows attributable to such assets, including but not limited to cash received from the Boeing license and the probability and extent of our participation in the U.S. Department of Homeland Security’s (“DHS”) next generation BioWatch program and the what we believe to be a large market opportunity for our Firefly Dx product, once development is complete. Based on our analysis, we have concluded based on information currently available, that no impairment of the intangible assets exists as of June 30, 2015. The Company performed an impairment test of goodwill as indicators were present as of June 30, 2015. As a result of this test, using the market capitalization method of valuation, it was determined that the goodwill balance of $ 510,000 The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into common shares at a fixed discount to the price of the common stock at the time of conversion. The Company measures the fair value of the notes at the time of issuance, which is the result of the share price discount at the time of conversion, and records the premium as accretion to interest expense to the date of first conversion. The Company accounts for debt issuance cost paid to lenders, or on behalf of lenders, in accordance with ASC 470, Debt. The costs associated with the issuance of debt are recorded as debt discount and amortized over the life of the underlying debt instrument. The Company evaluates its convertible debt, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. The result of this accounting treatment is that under certain circumstances the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under this accounting standard are reclassified to liability at the fair value of the instrument on the reclassification date. Revenue is recognized when persuasive evidence of an arrangement exists, collectability of arrangement consideration is reasonably assured, the arrangement fees are fixed or determinable and delivery of the product or service has been completed. If at the outset of an arrangement, the Company determines that collectability is not reasonably assured, revenue is deferred until the earlier of when collectability becomes probable or the receipt of payment. If there is uncertainty as to the customer’s acceptance of the Company’s deliverables, revenue is not recognized until the earlier of receipt of customer acceptance or expiration of the acceptance period. If at the outset of an arrangement, the Company determines that the arrangement fee is not fixed or determinable, revenue is deferred until the arrangement fee becomes estimable, assuming all other revenue recognition criteria have been met. To date, the Company has generated revenue from two sources: (1) professional services (consulting & advisory), and (2) technology licensing. Specific revenue recognition criteria for each source of revenue is as follows: (1) Revenues for professional services, which are of short term duration, are recognized when services are provided, (2) Technology license revenue is recognized upon the completion of all terms of that license. Payments received in advance of completion of the license terms are recorded as deferred revenue. The Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with ASC Topic 820, Fair Value Measurements and Disclosures ASC Topic 820 provides guidance with respect to valuation techniques to be utilized in the determination of fair value of assets and liabilities. Approaches include, (i) the market approach (comparable market prices), (ii) the income approach (present value of future income or cash flow), and (iii) the cost approach (cost to replace the service capacity of an asset or replacement cost). ASC Topic 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. The Company presents basic income (loss) per common share and, if applicable, diluted income (loss) per share. Basic income (loss) per common share is based on the weighted average number of common shares outstanding during the year and after preferred stock dividend requirements. The calculation of diluted income (loss) per common share assumes that any dilutive convertible preferred shares outstanding at the beginning of each year or the date issued were convertible at those dates, with preferred stock dividend requirements and outstanding common shares adjusted accordingly. It also assumes that outstanding common shares were increased by shares issuable upon exercise of those stock options and warrants for which the average period market price exceeds the exercise price, less shares that could have been purchased by the Company with related proceeds. Additionally, shares issued upon conversion of convertible debt are included. June 30, 2015 2014 Common shares issuable under: Convertible notes 219,655 40,109 Series I Convertible preferred stock 62,946 36,995 Series F Convertible preferred stock — 17,487 Stock options 4,696 2,857 Warrants 4,490 2,490 Unvested and restricted shares common stock 3,432 3,432 295,219 103,370 The Company operates in a single market segment.

Acquisitions_Dispositions

Acquisitions/Dispositions	6 Months Ended
	Jun. 30, 2015
Disclosure Text Block Supplement [Abstract]
Mergers, Acquisitions and Dispositions Disclosures [Text Block]	3. Acquisitions/Dispositions Sale of VeriChip Business to Former Related Party In a series of transactions between 2012 and 2014 PositiveID first licensed and subsequently sold all of the intellectual property related to its VeriChip implantable microchip business to VeriTeQ Corporation, a business run by a former related party (CEO of the Company through 2011). The final agreement in the series was the GlucoChip Agreement, dated October 20, 2014. Pursuant to the VeriTeQ agreements, the Company holds a Note that was received as payment for shared services payments that the Company made on behalf of VeriTeQ during 2011 and 2012 which Note had an original value of $222,115. The note has been fully reserved in all periods presented. The Company also holds a five year warrant dated November 13, 2013, with original terms entitling the Company to purchase 300,000 shares of VeriTeQ common stock at a price of $2.84. Pursuant to the terms of the warrant, in particular the full quantity and pricing reset provisions, the warrant had an original dollar value of $852,000 and can be exercised using a cashless exercise feature. Pursuant to the GlucoChip Agreement, the Company transferred the intellectual property related to its GlucoChip development and agreed to provide financial support to VeriTeQ, for a period of up to two years, in the form of convertible promissory notes. The Company funded VeriTeQ $60,000 in 2014 and $110,000 during the six months ended June 30, 2015 and VeriTeQ issued the Company Convertible Promissory Notes in total principal amount of $170,000. These notes have been fully reserved in all periods presented. The notes bear interest at the rate of 10% per annum; are due and payable twelve months from the effective date of the notes; and may be converted by the Company at any time after 190 days of the date of closing into shares of VeriTeQ common stock at a conversion price equal to a 40% discount of the average of the three lowest daily trading prices (as set forth in the notes) calculated at the time of conversion. The notes also contains certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates in the event of such defaults. Pursuant to the GlucoChip Agreement, the Company agreed to provide VeriTeQ with continuing financial support through issuance of additional convertible promissory notes with similar terms and conditions as the original note up to an additional amount of $230,000 (see Note 7). The continuing financial support is not required to be more frequent than every 100 days and may not be in excess of $50,000 in any individual note. As of June 30, 2015 the Company had convertible notes receivable from VeriTeQ of $392,115. As of December 31, 2014 and June 30, 2015 the Company had a dollar value balance remaining on it cashless exercise warrant from VeriTeQ of $820,010 and $733,977, respectively. Pursuant to the cashless exercise feature of the VeriTeQ warrant, the Company realized $224,000 and $319,400 of income during the three and six months ended June 30, 2015, respectively. Proceeds from the cashless exercise of the VeriTeQ warrant was measured at fair value at the time of the sale and reported as other income. As VeriTeQ is an early stage company, not yet fully capitalized, the Company plans to continue to fully reserve all note receivable and warrant balances. If and when proceeds are realized in the future, gains will be recognized. License of iglucose On February 15, 2013, the Company entered into an agreement the (“SGMC Agreement”) with SGMC, and its affiliates, pursuant to which the Company entered into a perpetual license to its iglucose Pursuant to the SGMC Agreement, the Company granted SGMC an exclusive right and license to the intellectual property rights in the iglucose iglucose iglucose iglucose In consideration for the rights and licenses discussed above, and the transfer of the domain names, SGMC shall pay to the Company the amount set forth below for each glucose test strip sold by SGMC and any sublicenses of SGMC for which results are posted by SGMC via its communications servers (the “Consideration”): (i) $0.0025 per strip sold until SGMC has paid aggregate Consideration of $1,000,000; and (ii) $0.005 per strip sold thereafter until SGMC has paid aggregate Consideration of $2,000,000; provided, however, that the aggregate Consideration payable by SGMC pursuant to the SGMC Agreement shall in no event exceed $2,000,000. To date, no royalties have been realized from this agreement.

Equity and Debt Financing Agree

Equity and Debt Financing Agreements	6 Months Ended
	Jun. 30, 2015
Equity And Debt Financing Agreements Disclosure [Abstract]
Equity And Debt Financing Agreements Disclosure [Text Block]	4. Equity and Debt Financing Agreements Convertible Note Financings Accrued Notes Interest Total Convertible notes with embedded derivatives $ 4,438 $ 302 $ 4,740 Derivative discounts (3,071) — (3,071) 1,367 302 1,669 Original issue discounts and loan fee discounts (467) — (467) $ 900 $ 302 $ 1,202 $4 Million Convertible Debt Financing On November 25, 2014 the Company closed a financing transaction by entering into a Securities Purchase Agreement dated November 25, 2014 (the “SPA”) with Dominion Capital LLC (the “Purchaser”) for an aggregate subscription amount of $ 4,000,000 500,000 th 25,000 25,000 The total principal amount of the Notes are issued with a 4 4,000,000 3,840,000 12 95 62.5 120 In connection with the Company’s obligations under the Note, the Company entered into a Security Agreement with the Purchaser, pursuant to which the Company granted a lien on all assets of the Company, subject to existing security interests, (the “Collateral”) for the benefit of the Purchaser, to secure the Company’s obligations under the Note. In the event of a default as defined in the Note, the Purchaser may, among other things, collect or take possession of the Collateral, proceed with the foreclosure of the security interest in the Collateral or sell, lease or dispose of the Collateral. Through June 30, 2015, the Company has received all eight tranches under the SPA of the Note ($ 500,000 3,650,000 150,000 500,000 3,540,600 Other Convertible Debt Financing On March 13, 2014, the Company borrowed two notes of $75,000, each from a separate lender with maturity dates of March 4, 2015. Under each agreement the Company received $65,750, which was net of legal and due diligence fees. The notes bear interest at 8% per annum and are convertible at the option of the lender into shares of the Company’s common stock at a 40% discount to the lowest closing bid price in the 20 trading days prior to conversion. The notes might be accelerated if an event of default occurs under the terms of the note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. In conjunction with each note the Company also issued an additional note, of identical terms, each for $75,000. The additional note was paid for by the issuance of a note payable from the lenders to the Company. In the event that the original note is not repaid prior to six months from its issuance, the lender has the option of converting the additional note into shares of the Company’s common stock at a 40% discount to lowest closing bid price in the 20 trading days prior to conversion, subject to the notes payable to the Company having been paid in full. The additional note payable has been netted with the related note receivable. In connection with the issuance of the notes, the Company computed a premium of $100,000 as the debt is considered a stock settled debt under ASC 480, all of which was amortized during the year ended December 31, 2014. As of March 31, 2015, the outstanding principal and interest was converted, into 16,386,485 shares of common stock. On May 5, 2014 one of the $75,000 notes receivable due to the company was paid, for which the Company received $65,750, net of fees. The Company computed a premium of $50,000 as the debt is considered a stock settled debt under ASC 480, all of which was amortized during the year ended December 31, 2014. As of March 31, 2015, the outstanding principal and interest was converted, into 4,117,795 shares of common stock. Concurrent with the repayment the Company and the lender entered into two new convertible notes, for $75,000 each, on identical terms to the March 4, 2014 convertible notes. Each of these two notes was paid for by the issuance of notes payable from the lenders to the Company, each for $75,000, on identical terms to the March 4, 2014 notes. These two new notes have been netted for presentation purposes. In connection with the payment of the note receivable to the Company, the Company recorded a premium of $50,000 for each of the additional notes that had been entered into on March 4, 2014, all of which was amortized during the year ended December 31, 2014. As of March 31, 2015, the outstanding principal and interest for both notes was converted, into 9,482,870 shares of common stock. On June 18, 2014, the Company closed a financing agreement whereby the Company borrowed an aggregate principal amount of $165,000 with a 10% original note discount. The note has an interest rate of 10%, and is convertible at the option of the lender into shares of the Company’s common stock at the lesser of (i) a 40% discount to the lowest closing bid price in the 20 trading days prior to conversion or (ii) $0.075. The note might be accelerated if an event of default occurs under the terms of the note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. The first tranche was funded on June 18, 2014 with a principal amount of $55,000 and net proceeds of $50,000, with a maturity date of June 17, 2016, pursuant to the convertible note. In connection with the issuance of the note, the Company recorded a debt discount of $50,000 related to the derivative liability which was fully amortized as of June 30, 2015. As of June 30, 2015, the outstanding principal and interest of the note was fully converted into 4,425,894 shares of common stock. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $59,623 was recorded when the note was entered into. The derivative liability was re-measured at each balance sheet date and was reclassified to equity upon conversion of the note. On July 3, 2014, the Company borrowed $115,000 with a maturity date of July 3, 2015, pursuant to a convertible note. Under the agreement the Company received $100,000, which was net of legal and due diligence fees. The Note has an interest rate of 8%, and is convertible at the option of the lender into shares of the Company’s common stock at the lesser of $0.06 per share or a 40% discount of the lowest closing bid prices in the 15 trading days prior to conversion. The note might be accelerated if an event of default occurs under the terms of the note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. In connection with the issuance of the notes, the Company recorded a debt discount of $58,571 relating to derivative liability which was fully amortized as of March 31, 2015. As of March 31, 2015, the outstanding principal and interest on the note was fully converted into 8,248,677 shares of common stocks. In conjunction with the Note, the Company granted the lender a warrant for 1,000,000 common shares at a strike price of $0.08. The warrant has a life of three years and its relative fair value of $41,429 has been recorded as a debt discount and additional paid in capital as of March 31, 2015. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $59,623 was recorded when the note was entered into. The derivative liability was re-measured at each balance sheet date and was reclassified to equity on a pro-rata basis upon conversion of the note. On July 7, 2014, the Company borrowed $53,000 with a maturity date of March 25, 2015, pursuant to a financing agreement. Under the agreement the Company received $50,000, which was net of legal fees. The note bears interest at 8% per annum and is convertible at the option of the lender into shares of the Company’s common stock at a 39% discount to the price of common shares in the 10 days prior to conversion. The note might be accelerated if an event of default occurs under the terms of the note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. In connection with the issuance of the note, the Company computed a premium of $33,885 as the note is considered stock settled debt under ASC 480, all of which was accreted and charged to interest expense in the year ended December 31, 2014. During the quarter ended June 30, 2015, the Company exercised its right to prepay the outstanding principal and interest for a total redemption amount of $73,629 and recorded a loss on extinguishment of approximately $18,550. On July 9, 2014 and August 21, 2014 the Company borrowed from a lender, notes each amounting to $110,000 which matures twelve months from the date of the respective notes, pursuant the agreement. Each debt was issued at a 10% original issue discount resulting in net total proceeds of $180,000, net of legal fees. The notes bear an interest rate of 10%, and are convertible at the option of the lender into shares of the Company’s common stock at a 40% discount to the lowest closing bid price during the 15 days prior to the election to conversion. The notes could have been accelerated if an event of default occurs under the terms of the note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. In connection with the issuance of the note, the Company computed a total premium of $146,666 as the notes were considered stock settled debt under ASC 480. On December 30, 2014, the Lender and Dominion Capital LLC entered into a purchase and assignment of these notes. Subsequent to the purchase and assignment, the note was amended by the Company and the Purchaser, using the form of note identical to the notes used in the $4 Million Financing Agreement. The Company issued a new note for $222,222 convertible at the lesser of a 37.5% discount to the common stock price on the date of the note or a 37.5% discount to the price of our common stock price at the time of conversion. In conjunction with the purchase and assignment, the Company and Purchaser entered into a new note with a principal value of $49,444 as compensation for Purchaser’s costs related to the purchase and assignment. This $49,444 was expensed as a loss on debt extinguishment. In connection with the issuance of the notes, the Company recorded a debt discount of $271,666 related to the embedded conversion option derivative liability which was fully amortized as of June 30, 2015. During the quarter ended June 30, 2015, $175,000 of the outstanding principal and interest on the notes was converted into 15,074,906 shares of common stock. As of June 30, 2015, the outstanding principal and interest was $65,610. As the note conversions includes a “lesser of” pricing provision, a derivative liability of $289,701 was recorded when these notes were entered into. The derivative liability was re-measured at each balance sheet date and reclassified to equity on a pro-rata basis upon conversion of the note, the derivative liability balance at June 30, 2015 was $41,255. On July 17, 2014, the Company borrowed $115,000 with a maturity date of July 17, 2016, pursuant to a convertible note. The debt was issued at a 10% original issue discount resulting in proceeds of $100,000, has an interest rate of 10%, and is convertible at the option of the lender into shares of the Company’s common stock at the lesser of $0.06 per share or a 40% discount of the lowest closing bid prices in the 20 trading days prior to conversion. The note might be accelerated if an event of default occurs under the terms of the note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. In connection with the issuance of the notes, the Company recorded a debt discount of $100,000 related to the derivative liability which was fully was fully amortized as of March 31, 2015. On January 8, 2015, the Company exercised its right to prepay the outstanding principal and interest for a total redemption amount of $120,750. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $124,666 was recorded when the note was entered into. The derivative liability was re-measured at each balance sheet date and was reclassified to equity on a pro-rata basis upon redemption of the note. On August 19, 2014, the Company borrowed $66,000 with a maturity date of August 15, 2015, pursuant to a convertible note. The debt was issued at a 10% original issue discount resulting in proceeds of $54,500, net of legal fees. The Note has an interest rate of 8%, and is convertible at the option of the lender into shares of the Company’s common stock at the lesser of $0.06 per share or a 60% of the average of the three lowest closing bid prices 15 trading days prior to conversion. The note might be accelerated if an event of default occurs under the terms of the note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. In connection with the issuance of the notes, the Company recorded a debt discount of $54,500 related to the derivative liability which was fully amortized as of March 31, 2015. As of March 31, 2015, the outstanding principal and interest on the note was fully converted into 5,000,000 shares of common stock. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $71,548 was recorded when the note was entered into. The derivative liability was re-measured at each balance sheet date and was reclassified to equity on a pro-rata basis upon conversion of the note. On September 4, 2014, the Company borrowed $ 110,000 10,000 100,000 10 60 100,000 9,195,341 119,246 On September 22, 2014, Company closed a Securities Purchase Agreement providing for the purchase of two Convertible Redeemable Notes in the aggregate principal amount of $ 100,000 8 40 50,000 45,000 33,333 5,095,904 50,000 50,000 33,333 5,210,553 On September 22, 2014, the Company borrowed $ 54,750 50,000 8 40 36,500 56,778 4 24,772 On September 24, 2014, the Company borrowed $ 75,000 8 67,750 40 50,000 4,955,411 On March 10, 2015, the Company issued a new note for $ 56,778 24,772 24,772 81,500 60,440 54,750 3,560,976 30,070 96,915 24,921 On October 6, 2014, the Company borrowed $ 53,000 50,000 8 39 33,885 73,641 On October 8, 2014, the Company borrowed $ 100,000 85,500 7,000 7,500 10 40 66,667 7,590,186 On October 27, 2014, the Company borrowed $ 36,750 33,250 8 40 24,500 52,892 14,700 On October 27, 2014, the Company borrowed $ 161,000 150,000 11,000 8 40 1,000,000 33,404 107,333 166,681 4 88,319 On April 6, 2015, the Company issued a new note for $ 166,681 88,319 88,319 255,000 89,889 120,750 12,000,000 143,075 305,904 180,152 Convertible Debenture Financing On December 24, 2014, the Ironridge and Dominion Capital LLC entered into a purchase and assignment of the debenture owned by Ironridge, and the Company and Dominion amended the Debenture, with the total amount owed as of December 24, 2014 at $ 434,592 4 158,400 In connection with the issuance of the Debenture and the Note, the Company recorded a debt discount of $ 522,061 631,993 48,129,507 24,138 571,387 11,230 Other Financings On July 9, 2012, the Company issued a Secured Promissory Note (the “H&K Note”) in the principal amount of $ 849,510 750,000 1,500,000 750,000 3,000,000 397,061 452,499 On September 7, 2012, the Company issued a Secured Promissory Note (the “Caragol Note”) in the principal amount of $ 200,000 200,000 5 1,500,000 100,000 57,488 On April 27, 2015, the Company issued two separate convertible notes to consultants, each note in the principal amount of $ 62,500 8 0.02 75 125,000 8,992 126,753 156,750 148,065 Embedded Conversion Option Derivatives Due to the conversion terms of certain promissory notes, the embedded conversion options met the criteria to be bifurcated and presented as derivative liabilities. Note Inception Date June 30, 2015 Volatility 188- 374 % 224 % Expected Term 0.4 - 1.5 years 0.01- 1.5 years Risk Free Interest Rate 0.12 - 2 % 0.28 % Embedded conversion option liability fair value as of December 31, 2014 $ 2,152 Note inception date fair value allocated to debt discount 3,615 Note inception date fair value allocated to other expense 1,898 Reclassification of derivative liability to equity upon debt conversion (1,241) Change in fair value during six months ended June 30, 2015 (721) Embedded conversion option liability fair value as of June 30, 2015 $ 5,703 Fair Value Measurements We currently measure and report at fair value the liability for embedded conversion option derivatives. The fair value liabilities for price adjustable convertible debt instruments have been recorded as determined utilizing the BSM option pricing model as previously discussed. Quoted Prices in Active Significant Balance at Markets for Other Significant June 30, Identical Observable Unobservable 2015 Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Liabilities: Fair value of liability for embedded conversion option derivative instruments $ 5,703 $ - $ - $ 5,703

Stockholders' Deficit

Stockholders' Deficit	6 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	5. Stockholder’s Deficit On August 26, 2011, the Company’s stockholders approved and adopted the PositiveID Corporation 2011 Stock Incentive Plan (the “2011 Plan”). The 2011 Plan provides for awards of incentive stock options, nonqualified stock options, restricted stock awards, performance units, performance shares, SARs and other stock-based awards to employees and consultants. Under the 2011 Plan, up to 1 Weighted Average Number of Exercise Price Options Per Share Outstanding at December 31, 2014 2,856 $ 1.26 Granted 1,840 $ 0.01 Exercised — $ — Forfeited — $ — Outstanding at June 30, 2015 4,696 $ 0.78 Exercisable at June 30, 2015 4,006 $ 0.91 The Black-Scholes model, which the Company uses to determine compensation expense, requires the Company to make several key judgments including: • the value of the Company’s common stock; • the expected life of issued stock options; • the expected volatility of the Company’s stock price; • the expected dividend yield to be realized over the life of the stock option; and • the risk-free interest rate over the expected life of the stock options. The Company’s computation of the expected life of issued stock options was determined based on historical experience of similar awards giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations about employees’ future length of service. The interest rate was based on the U.S. Treasury yield curve in effect at the time of grant. The computation of volatility was based on the historical volatility of the Company’s common stock. Unvested at December 31, 2014 200 Issued — Vested (100) Forfeited — Unvested at June 30, 2015 100 Additionally, the Company has 3.2 4.5 0.06 0.75 The Company issued 6.3 147,900 The Company recorded an expense related to stock options, restricted stock issued, and issuance of Series I Preferred to employees and advisors of approximately $ 0.2 0.3 1.2 1.4 As of June 30, 2015 the Company had $ 0.2 Series I Preferred Stock On September 30, 2013 the Board of Directors authorized and in November 2013 the Company filed with the State of Delaware, a Certificate of Designations of Preferences, Rights and Limitations of Series I Preferred Stock (the “Certificate”). The Series I Preferred Stock ranks junior to the Company’s Series F Preferred Stock and to all liabilities of the Company and is senior to the Common Stock and any other preferred stock. The Series I Preferred Stock has a stated value per share of $ 1,000 6 400 On September 30, 2013, the Company issued 413 413,000 0.036 On November 5, 2013, the Company filed an Amended and Restated Certificate of Designation of Series I Preferred Stock (the “Amended Certificate of Designation”). The Amended Certificate of Designation was filed to clarify and revise the mechanics of conversion and certain conversion rights of the holders of Series I Preferred Stock. No other rights were modified or amended in the Amended Certificate of Designation. On January 8, 2015, the Company filed an amendment to the Amended Certificate of Designation to increase the authorized shares of Series I Convertible Preferred Stock from 1,000 2,500 On December 31, 2013, the three independent directors were each granted 25 512 381 138 143 200,000 100 187,500 On January 9, 2015, shares of Series I were issued as follows: (i) 50 150 475 0.027 812,500 January 1, 2017

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	6. Income Taxes The Company had an effective tax rate of nil for the three and six months ended June 30, 2015 and 2014. The Company incurred losses before taxes for the three and six months ended June 30, 2015 and 2014. However, it has not recorded a tax benefit for the resulting net operating loss carryforwards, as the Company has determined that a full valuation allowance against its net deferred tax assets was appropriate based primarily on its historical operating results. In July 2008, the Company completed the sale of all of the outstanding capital stock of Xmark to Stanley. In January 2010, Stanley received a notice from the Canadian Revenue Agency (“CRA”) that the CRA would be performing a review of Xmark’s Canadian tax returns for the periods 2005 through 2008. This review covers all periods that the Company owned Xmark. In February 2011, and as revised on November 9, 2011, Stanley received a notice from the CRA that the CRA completed its review of the Xmark returns and was questioning certain deductions attributable to allocations from related companies on the tax returns under review. In November and December 2011, the CRA and the Ministry of Revenue of the Province of Ontario issued notices of reassessment confirming the proposed adjustments. The total amount of the income tax reassessments for the 2006-2008 tax years, including both provincial and federal reassessments, plus interest, was approximately $ 1.4 On January 20, 2012, the Company received an indemnification claim notice from Stanley related to the matter. The Company did not agree with the position taken by the CRA, and filed a formal appeal related to the matter on March 8, 2012. In addition, on March 28, 2012, Stanley received assessments for withholding taxes on deemed dividend payments in respect of the disallowed management fee totaling approximately $ 0.2 950,000 220,000 24 545,777 On February 28, 2014 the Company received final notice from the CRA. The Company has determined that it will not further appeal the decision in the final notice. The Company and Stanley are in the process of submitting the tax forms necessary to effect the final adjustments. While the final accounting is being coordinated with CRA, the Company paid $ 140,000 345,000

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	7. Commitments and Contingencies Lease Commitments The Company leases certain office space under noncancelable operating leases, including the Company’s corporate offices in Delray Beach, Florida under a lease scheduled to expire in October 18, 2018 April 2015 45,000 61,000 Other Commitments Pursuant to the GlucoChip Agreement (see Note 3), the Company also agreed to provide financial support to VeriTeQ, for a period of up to two years, in the form of convertible promissory notes. The Company funded VeriTeQ $ 60,000 110,000 230,000 Legal Proceedings The Company is a party to certain legal actions, as either plaintiff or defendant, arising in the ordinary course of business, none of which is expected to have a material adverse effect on the Company’s business, financial condition or results of operations. However, litigation is inherently unpredictable, and the costs and other effects of pending or future litigation, governmental investigations, legal and administrative cases and proceedings, whether civil or criminal, settlements, judgments and investigations, claims or charges in any such matters, and developments or assertions by or against the Company relating to the Company or to the Company’s intellectual property rights and intellectual property licenses could have a material adverse effect on the Company’s business, financial condition and operating results.

Employment Contracts and Stock

Employment Contracts and Stock Compensation to Related Parties	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	8. Employment Contracts and Stock Compensation to Related Parties On December 6, 2011, the Compensation Committee approved a First Amendment to Employment and Non-Compete Agreement (the “First Caragol Amendment”) between the Company and Mr. Caragol in connection with Mr. Caragol’s assumption of the position of Chairman of the Board of the Company effective December 6, 2011. The First Caragol Amendment amends the Employment and Non-Compete Agreement dated November 11, 2010, between the Company and Mr. Caragol and provides for, among other things, the elimination of any future guaranteed raises and bonuses, other than a 2011 bonus of $375,000 to be paid beginning January 1, 2012 in twelve (12) equal monthly payments. This bonus was not paid during 2012 and on January 8, 2013, $300,000 of such bonus was converted into 738,916 shares of our restricted common stock, which vest on January 1, 2016. The remaining $75,000 was paid through the issuance of Series I Preferred Stock (see below). The First Caragol Amendment obligates the Company to grant to Mr. Caragol an aggregate of 0.5 million shares of restricted stock over a four-year period as follows: (i) 100,000 shares upon execution of the First Caragol Amendment, which shall vest on January 1, 2014, (ii) 100,000 shares on January 1, 2012, which shall vest on January 1, 2015, (iii) 100,000 shares on January 1, 2013, which shall vest on January 1, 2015, (iv) 100,000 shares on January 1, 2014, which shall vest on January 1, 2016, and (v) 100,000 shares on January 1, 2015, which shall vest on January 1, 2016. Stock compensation expense related to the restricted share grants totaled approximately $68,000 and $67,000 for the six months ended June 30, 2015 and 2014, respectively. On January 14, 2014, Mr. Caragol’s agreement was further amended, lowering his salary to $200,000 per annum through the remaining term of the agreement in exchange for the issuance of 143 shares of Series I Preferred Stock. On September 28, 2012, the employment of Bryan D. Happ, our chief financial officer terminated. In connection with the termination of Happ’s Employment and Non-Compete Agreement dated September 30, 2011, we and Mr. Happ entered into a Separation Agreement and General Release, or the Separation Agreement, on September 28, 2012. Pursuant to the Separation Agreement, Mr. Happ was due to receive payments totaling $404,423, or the Compensation, consisting of past-due accrued and unpaid salary and bonus amounts plus termination compensation. Of the Compensation, $100,000 was paid with 200,000 shares of our restricted common stock (such shares not issued under a stockholder approved plan) and $304,423 was to be paid in cash. As of June 30, 2015, we have paid $201,680 of the cash balance to Mr. Happ and the remaining outstanding amount accrued as of June 30, 2015 was approximately $102,000.

Agreements with The Boeing Comp

Agreements with The Boeing Company	6 Months Ended
	Jun. 30, 2015
License Agreements [Abstract]
License Agreements [Text Block]	9. Agreements with The Boeing Company On December 20, 2012, the Company entered into a Sole and Exclusive License Agreement (the “Boeing License Agreement”), a Teaming Agreement (“Teaming Agreement”), and a Security Agreement (“Boeing Security Agreement”) with The Boeing Company (“Boeing”). The Boeing License Agreement provides Boeing the exclusive license to manufacture and sell PositiveID’s M-BAND airborne bio-threat detector for the DHS’s BioWatch next generation opportunity, as well as other opportunities (government or commercial) that may arise in the North American market. As consideration for entering into the Boeing License Agreement, Boeing agreed to pay a license fee of $ 2.5 2.5 At the time of entering into the Boeing Teaming and License Agreements we evaluated the Boeing license revenue recognition and concluded that all elements necessary to complete the earnings process were complete as of the date of receipt of the $2.5 million of license fees, with the exception of the completion of the terms of the Teaming Agreement, which is a delivery requirement. Under the Teaming Agreement, the Company retained exclusive rights to serve as the reagent and assay supplier of the M-BAND systems to Boeing. The Company also retained the rights to sell M-BAND units, reagents and assays in international markets. Upon the Teaming Agreement expiring, terminating or being replaced by a contact or subcontract, the Company expects to recognize the deferred revenue related to the Boeing License Agreement. Pursuant to the Boeing Security Agreement, the Company granted Boeing a security interest in all its assets, including the licensed products and intellectual property rights (as defined in Boeing License Agreement), to secure the Company’s performance under the Boeing License Agreement.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	10. Subsequent Events Subsequent to June 30, 2015: • Convertible notes with principal and interest value of $367,352 have been converted into 31,086,144 shares of common stock. • The Company funded VeriTeQ $15,000 and VeriTeQ issued the Company a convertible promissory note, pursuant to the GlucoChip Agreement (additional information disclosed in Note 7), in the same amount.

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries of which all are inactive except for MFS. All significant intercompany transactions have been eliminated in the consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates during the reported periods include allowance for doubtful accounts receivable, valuation of goodwill and intangible assets, valuation of derivatives, valuation of beneficial conversion features, estimate of the contingent earn-out liability, valuation of stock-based compensation and an estimate of the deferred tax asset valuation allowance.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Intangible Assets and Goodwill Intangible assets are carried at cost less accumulated amortization, computed using the straight-line method over the estimated useful lives. Customer contracts and relationships were previously being amortized over 3 5 2 The Company continually evaluates whether events or circumstances have occurred that indicate the remaining estimated useful lives of its definite-lived intangible assets may warrant revision or that the remaining balance of such assets may not be recoverable. The Company uses an estimate of the related undiscounted cash flows attributable to such asset over the remaining life of the asset in measuring whether the asset is recoverable. The Company records goodwill as the excess of the purchase price over the fair values assigned to the net assets acquired in business combinations. Goodwill is allocated to reporting units as of the acquisition date for the purpose of goodwill impairment testing. The Company’s reporting units are those businesses for which discrete financial information is available and upon which segment management makes operating decisions. Goodwill of a reporting unit is tested for impairment at year-end, or between testing dates if an impairment condition or event is determined to have occurred. In assessing potential impairment of the intangible assets recorded in connection with the MFS acquisition as of June 30, 2015, we considered the likelihood of future cash flows attributable to such assets, including but not limited to cash received from the Boeing license and the probability and extent of our participation in the U.S. Department of Homeland Security’s (“DHS”) next generation BioWatch program and the what we believe to be a large market opportunity for our Firefly Dx product, once development is complete. Based on our analysis, we have concluded based on information currently available, that no impairment of the intangible assets exists as of June 30, 2015. The Company performed an impairment test of goodwill as indicators were present as of June 30, 2015. As a result of this test, using the market capitalization method of valuation, it was determined that the goodwill balance of $ 510,000
Debt, Policy [Policy Text Block]	Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into common shares at a fixed discount to the price of the common stock at the time of conversion. The Company measures the fair value of the notes at the time of issuance, which is the result of the share price discount at the time of conversion, and records the premium as accretion to interest expense to the date of first conversion. The Company accounts for debt issuance cost paid to lenders, or on behalf of lenders, in accordance with ASC 470, Debt. The costs associated with the issuance of debt are recorded as debt discount and amortized over the life of the underlying debt instrument.
Derivatives, Policy [Policy Text Block]	Accounting for Derivatives The Company evaluates its convertible debt, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. The result of this accounting treatment is that under certain circumstances the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under this accounting standard are reclassified to liability at the fair value of the instrument on the reclassification date.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Revenue is recognized when persuasive evidence of an arrangement exists, collectability of arrangement consideration is reasonably assured, the arrangement fees are fixed or determinable and delivery of the product or service has been completed. If at the outset of an arrangement, the Company determines that collectability is not reasonably assured, revenue is deferred until the earlier of when collectability becomes probable or the receipt of payment. If there is uncertainty as to the customer’s acceptance of the Company’s deliverables, revenue is not recognized until the earlier of receipt of customer acceptance or expiration of the acceptance period. If at the outset of an arrangement, the Company determines that the arrangement fee is not fixed or determinable, revenue is deferred until the arrangement fee becomes estimable, assuming all other revenue recognition criteria have been met. To date, the Company has generated revenue from two sources: (1) professional services (consulting & advisory), and (2) technology licensing. Specific revenue recognition criteria for each source of revenue is as follows: (1) Revenues for professional services, which are of short term duration, are recognized when services are provided, (2) Technology license revenue is recognized upon the completion of all terms of that license. Payments received in advance of completion of the license terms are recorded as deferred revenue.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with ASC Topic 820, Fair Value Measurements and Disclosures ASC Topic 820 provides guidance with respect to valuation techniques to be utilized in the determination of fair value of assets and liabilities. Approaches include, (i) the market approach (comparable market prices), (ii) the income approach (present value of future income or cash flow), and (iii) the cost approach (cost to replace the service capacity of an asset or replacement cost). ASC Topic 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.
Earnings Per Share, Policy [Policy Text Block]	Loss per Common Share The Company presents basic income (loss) per common share and, if applicable, diluted income (loss) per share. Basic income (loss) per common share is based on the weighted average number of common shares outstanding during the year and after preferred stock dividend requirements. The calculation of diluted income (loss) per common share assumes that any dilutive convertible preferred shares outstanding at the beginning of each year or the date issued were convertible at those dates, with preferred stock dividend requirements and outstanding common shares adjusted accordingly. It also assumes that outstanding common shares were increased by shares issuable upon exercise of those stock options and warrants for which the average period market price exceeds the exercise price, less shares that could have been purchased by the Company with related proceeds. Additionally, shares issued upon conversion of convertible debt are included. June 30, 2015 2014 Common shares issuable under: Convertible notes 219,655 40,109 Series I Convertible preferred stock 62,946 36,995 Series F Convertible preferred stock — 17,487 Stock options 4,696 2,857 Warrants 4,490 2,490 Unvested and restricted shares common stock 3,432 3,432 295,219 103,370
Segment Reporting, Policy [Policy Text Block]	Segment Information The Company operates in a single market segment.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following potentially dilutive equity securities outstanding as of June 30, 2015 and 2014 were not included in the computation of dilutive loss per common share because the effect would have been anti-dilutive (in thousands): June 30, 2015 2014 Common shares issuable under: Convertible notes 219,655 40,109 Series I Convertible preferred stock 62,946 36,995 Series F Convertible preferred stock — 17,487 Stock options 4,696 2,857 Warrants 4,490 2,490 Unvested and restricted shares common stock 3,432 3,432 295,219 103,370

Equity and Debt Financing Agr19

Equity and Debt Financing Agreements (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure Text Block Supplement [Abstract]
Schedule of Short-term Debt [Table Text Block]	Short-term convertible debt as of June 30, 2015 as follows (In thousands): Accrued Notes Interest Total Convertible notes with embedded derivatives $ 4,438 $ 302 $ 4,740 Derivative discounts (3,071) — (3,071) 1,367 302 1,669 Original issue discounts and loan fee discounts (467) — (467) $ 900 $ 302 $ 1,202
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	The Company calculated the estimated fair values of the liabilities for embedded conversion option derivative instruments at the original note inception dates and as of June 30, 2015 using the Black-Scholes option pricing model using the share prices of the Company’s stock on the dates of valuation and using the following ranges for volatility, expected term and the risk free interest rate at each respective valuation date, no dividend has been assumed for any of the periods: Note Inception Date June 30, 2015 Volatility 188- 374 % 224 % Expected Term 0.4 - 1.5 years 0.01- 1.5 years Risk Free Interest Rate 0.12 - 2 % 0.28 %
Fair Value, Option, Quantitative Disclosures [Table Text Block]	The following reflects the initial fair value on the note inception dates and changes in fair value through June 30, 2015: Embedded conversion option liability fair value as of December 31, 2014 $ 2,152 Note inception date fair value allocated to debt discount 3,615 Note inception date fair value allocated to other expense 1,898 Reclassification of derivative liability to equity upon debt conversion (1,241) Change in fair value during six months ended June 30, 2015 (721) Embedded conversion option liability fair value as of June 30, 2015 $ 5,703
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2015: Quoted Prices in Active Significant Balance at Markets for Other Significant June 30, Identical Observable Unobservable 2015 Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Liabilities: Fair value of liability for embedded conversion option derivative instruments $ 5,703 $ - $ - $ 5,703

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	6 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of option activity under the Company’s stock incentive plans as of June 30, 2015, and changes during the six months ended is presented below (in thousands, except per share amounts): Weighted Average Number of Exercise Price Options Per Share Outstanding at December 31, 2014 2,856 $ 1.26 Granted 1,840 $ 0.01 Exercised — $ — Forfeited — $ — Outstanding at June 30, 2015 4,696 $ 0.78 Exercisable at June 30, 2015 4,006 $ 0.91
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	A summary of restricted stock outstanding under the Company’s stock incentive plans as of June 30, 2015 and changes during the six months then ended is presented below (in thousands): Unvested at December 31, 2014 200 Issued — Vested (100) Forfeited — Unvested at June 30, 2015 100

Organization and Basis of Pre21

Organization and Basis of Presentation (Details Textual) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Aug. 21, 2014	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Organization And Basis Of Presentation [Line Items]
Working Capital Deficiency		$ 10,100		$ 10,100		$ 8,100
Retained Earnings (Accumulated Deficit)		$ 139,551		$ 139,551		$ 132,757
Common Stock, Shares Authorized		1,970,000,000		1,970,000,000		1,970,000,000
Proceeds from Convertible Debt	$ 4,000			$ 2,600
Net Income (Loss) Attributable to Parent, Total		$ (2,933)	$ (1,063)	(6,794)	$ (3,372)
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total				$ (2,318)	$ (1,038)
Common Stock [Member]
Organization And Basis Of Presentation [Line Items]
Common Stock, Shares Authorized		1,970,000,000		1,970,000,000
Net Income (Loss) Attributable to Parent, Total				$ 0

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Details) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	295,219	103,370
Convertible notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	219,655	40,109
Convertible Series I Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	62,946	36,995
Convertible Series F Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	17,487
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,696	2,857
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,490	2,490
Unvested and restricted shares common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,432	3,432

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Significant Accounting Policies [Line Items]
Goodwill	$ 510	$ 510
Customer Contracts And Relationships [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	3 years
Patents [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 years
Non Compete Agreement [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	2 years

Acquisitions_Dispositions (Deta

Acquisitions/Dispositions (Details Textual) - Relationship to Entity [Domain]	Nov. 13, 2013USD ($)$ / sharesshares	Feb. 15, 2013USD ($)$ / Strip	Jun. 30, 2015USD ($)$ / shares	Jun. 30, 2015USD ($)$ / shares	Dec. 31, 2014USD ($)	Jun. 30, 2014USD ($)	Dec. 31, 2012USD ($)	Dec. 31, 2011USD ($)
Business Acquisition [Line Items]
Consideration For Rights And Licenses		$ 2,000,000
Debt Instrument, Face Amount			$ 170,000	$ 170,000
Number Of Strips Used Per Year		1,000
Debt Instrument, Description				The continuing financial support is not required to be more frequent than every 100 days and may not be in excess of $50,000 in any individual note.
Other Commitment, Due in Next Twelve Months			$ 230,000	$ 230,000
Price Range 0.0025 [Member]
Business Acquisition [Line Items]
License Revenue Per Strip | $ / Strip		0.0025
Consideration For Rights And Licenses		$ 1,000,000
Price Range 0.005 [Member]
Business Acquisition [Line Items]
License Revenue Per Strip | $ / Strip		0.005
Consideration For Rights And Licenses		$ 2,000,000
Minimum [Member]
Business Acquisition [Line Items]
License Revenue Per Strip | $ / Strip		0.0025
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 0.06	$ 0.06
Maximum [Member]
Business Acquisition [Line Items]
License Revenue Per Strip | $ / Strip		0.005
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 0.75	$ 0.75
Note II [Member]
Business Acquisition [Line Items]
Debt Instrument, Face Amount			$ 170,000	$ 170,000
Debt Instrument, Interest Rate During Period				10.00%
VeriTeQ warrant [Member]
Business Acquisition [Line Items]
Debt Instrument, Face Amount							$ 222,115
Trading Securities, Realized Gain			224,000	$ 319,400
Proceeds from Warrant Exercises				733,977	$ 820,010
VeriTeQ [Member]
Business Acquisition [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	300,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 2.84
Debt Instrument, Face Amount								$ 222,115
Proceeds from Warrant Exercises	$ 852,000
Notes Receivable, Related Parties, Current			392,115	$ 392,115
VeriTeQ [Member] | Note I [Member]
Business Acquisition [Line Items]
Debt Instrument Unamortized Discount Percentage				40.00%
VeriTeQ [Member] | Note II [Member]
Business Acquisition [Line Items]
Debt Instrument, Face Amount			$ 110,000	$ 110,000		$ 60,000

Equity and Debt Financing Agr25

Equity and Debt Financing Agreements (Details) - Jun. 30, 2015 - USD ($) $ in Thousands	Total
Convertible Notes With Embedded Derivatives [Member]
Short-term Debt [Line Items]
Notes Payable	$ 4,438
Debt Instrument, Increase, Accrued Interest	302
Short-term Debt, Maximum Amount Outstanding During Period	4,740
Derivative Discounts [Member]
Short-term Debt [Line Items]
Notes Payable	(3,071)
Debt Instrument, Increase, Accrued Interest	0
Short-term Debt, Maximum Amount Outstanding During Period	(3,071)
Convertible Notes With Embedded Derivatives Net [Member]
Short-term Debt [Line Items]
Notes Payable	1,367
Debt Instrument, Increase, Accrued Interest	302
Short-term Debt, Maximum Amount Outstanding During Period	1,669
Original issue discounts and loan fee discounts [Member]
Short-term Debt [Line Items]
Notes Payable	(467)
Debt Instrument, Increase, Accrued Interest	0
Short-term Debt, Maximum Amount Outstanding During Period	(467)
Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Notes Payable	900
Debt Instrument, Increase, Accrued Interest	302
Short-term Debt, Maximum Amount Outstanding During Period	$ 1,202

Equity and Debt Financing Agr26

Equity and Debt Financing Agreements (Details 1) - 6 months ended Jun. 30, 2015	Total
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility	224.00%
Risk Free Interest Rate	0.28%
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected Term	1 year 6 months
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected Term	4 days
Note Inception Date [Member] | Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility	374.00%
Expected Term	1 year 6 months
Risk Free Interest Rate	2.00%
Note Inception Date [Member] | Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility	188.00%
Expected Term	4 months 24 days
Risk Free Interest Rate	0.12%

Equity and Debt Financing Agr27

Equity and Debt Financing Agreements (Details 2) - Jun. 30, 2015 - USD ($) $ in Thousands	Total
Fair Value, Option, Quantitative Disclosures [Line Items]
Embedded conversion option liability fair value as of December 31, 2014	$ 2,152
Note inception date fair value allocated to debt discount	3,615
Note inception date fair value allocated to other expense	1,898
Reclassification of derivative liability to equity upon debt conversion	(1,241)
Change in fair value during six months ended June 30, 2015	(721)
Embedded conversion option liability fair value as of June 30, 2015	$ 5,703

Equity and Debt Financing Agr28

Equity and Debt Financing Agreements (Details 3) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Defined Benefit Plan Disclosure [Line Items]
Fair value of liability for embedded conversion option derivative instruments	$ 5,703	$ 2,152
Fair Value, Measurements, Recurring [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of liability for embedded conversion option derivative instruments	5,703
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of liability for embedded conversion option derivative instruments	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of liability for embedded conversion option derivative instruments	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of liability for embedded conversion option derivative instruments	$ 5,703

Equity and Debt Financing Agr29

Equity and Debt Financing Agreements (Details Textual) - Class of Stock [Domain] - USD ($)	Apr. 06, 2015	Mar. 10, 2015	Mar. 10, 2015	Nov. 25, 2014	Oct. 08, 2014	Oct. 06, 2014	Sep. 04, 2014	Jul. 07, 2014	May. 05, 2014	Mar. 13, 2014	Sep. 07, 2012	Apr. 27, 2015	Dec. 24, 2014	Oct. 27, 2014	Sep. 24, 2014	Sep. 22, 2014	Aug. 21, 2014	Aug. 19, 2014	Jul. 17, 2014	Jun. 18, 2014	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2015	Jun. 30, 2014	Jan. 08, 2015	Jul. 09, 2014	Jul. 03, 2014	Jul. 09, 2012
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt																	$ 4,000,000						$ 2,600,000
Debt Instrument, Face Amount																					$ 170,000		$ 170,000
Stock Issued During Period, Value, Conversion of Convertible Securities																					5,095,904
Common Stock Discount Percentage								39.00%									37.50%
Debt Conversion, Converted Instrument, Shares Issued																							31,086,144
Consultants [Member]
Equity And Debt Financing Agreements [Line Items]
Debt Instrument, Interest Rate, Stated Percentage												8.00%
Debt Instrument, Convertible, Conversion Price												$ 0.02
Debt Instrument, Face Amount												$ 62,500									126,753		$ 126,753
Derivative Liability												$ 156,750									148,065		148,065
Amortization of Debt Discount (Premium)																					8,992
Percentage Of Lowest Closing Price In 10 Trading Days												75.00%
Consultants [Member] | Derivative [Member]
Equity And Debt Financing Agreements [Line Items]
Amortization of Debt Discount (Premium)												$ 125,000
H K Note [Member]
Equity And Debt Financing Agreements [Line Items]
Repayments of Notes Payable																					397,061
Gross Proceeds Threshold From An Acquisition Or Disposition Of Assets																												$ 750,000
Gross Proceeds Threshold From Completion Of Any Financing																												1,500,000
Gross Proceeds Threshold From Receipt Of Any Revenues																												750,000
Gross Proceeds Threshold From Any One Financing Or Licensing Arrangement																												3,000,000
Secured Debt																					452,499		452,499					$ 849,510
Caragol Note [Member]
Equity And Debt Financing Agreements [Line Items]
Debt Instrument, Interest Rate, Stated Percentage											5.00%
Repayments of Notes Payable											$ 100,000
Secured Debt											200,000										57,488		$ 57,488
Financing Threshold Amount Triggering Accelerated Repayment Of Related Party Debt											1,500,000
Proceeds from Related Party Debt											$ 200,000
Convertible Note Financing On March 13, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities										9,482,870													4,117,795
Debt Instrument, Interest Rate, Stated Percentage										8.00%
Proceeds from Convertible Debt									$ 65,750
Convertible Debt										$ 75,000
Debt Instrument, Face Amount										$ 75,000
Stock Issued During Period, Value, Conversion of Convertible Securities																							$ 16,386,485
Debt Instrument, Maturity Date																							Mar. 4, 2015
Amortization of Debt Discount (Premium)																							$ 100,000
Percentage Of Lowest Closing Price In 20 Trading Days																							40.00%
Proceeds From Convertible Debt Gross																							$ 75,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs																							75,000
Debt Instrument, Unamortized Premium																					50,000		50,000
Convertible Note Financing On March 24, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt																							65,750
Convertible Note Financing On June 18 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Debt Instrument, Unamortized Discount																					50,000		50,000
Debt Instrument, Convertible, Conversion Price																				$ 0.075
Debt Instrument, Face Amount																				$ 165,000
Derivative Liability																					59,623		59,623
Stock Issued During Period, Value, Conversion of Convertible Securities																							$ 4,425,894
Debt Instrument, Maturity Date																							Jun. 17, 2016
Debt Discount As Percentage																				10.00%
Interest Charge As Percentage																				10.00%
Percentage Of Lowest Closing Price In 20 Trading Days																				40.00%
Convertible Note Financing On July 3, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Stock Issued During Period, Value, New Issues																							$ 1,000,000
Debt Instrument, Convertible, Conversion Price																											$ 0.06
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																											100,000
Debt Instrument, Face Amount																											$ 115,000
Derivative Liability																											$ 59,623
Stock Issued During Period, Value, Conversion of Convertible Securities																						$ 8,248,677
Debt Instrument, Maturity Date																							Jul. 3, 2015
Amortization of Debt Discount (Premium)																						58,571
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate																											8.00%
Percentage Of Lowest Closing Price In 15 Trading Days																											40.00%
Share Price																											$ 0.08
Warrants Not Settleable in Cash, Fair Value Disclosure																											$ 41,429
Convertible Note Financing On July 7, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt								$ 50,000
Convertible Debt																					73,629		$ 73,629
Debt Instrument, Face Amount								53,000
Debt Instrument, Maturity Date																							Mar. 25, 2015
Extinguishment Of Debt Write Off Of Unamortized Debt Discount																							$ 18,550
Amortization of Debt Discount (Premium)								$ 33,885
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate								8.00%
Convertible Note Financing On July 9, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Stock Issued During Period, Shares, New Issues																	49,444
Debt Instrument, Interest Rate, Stated Percentage																										10.00%
Proceeds from Convertible Debt																	$ 180,000
Convertible Debt																	222,222
Debt Instrument, Face Amount																	110,000				175,000		175,000
Derivative Liability																	$ 289,701				41,255		41,255
Percentage Of Discount On Common Shares Price Per Share																	37.50%
Amortization of Debt Discount (Premium)																	$ 271,666
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate																	10.00%
Conversion of Stock, Amount Converted																	$ 49,444
Percentage Of Lowest Closing Price In 15 Trading Days																	40.00%
Debt Instrument, Unamortized Premium																	$ 146,666
Debt Conversion, Converted Instrument, Shares Issued																	15,074,906
Debt, Current																	$ 65,610
Convertible Note Financing On July 17, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Debt Instrument, Unamortized Discount																					100,000		$ 100,000
Debt Instrument, Convertible, Conversion Price																			$ 0.06
Proceeds from Convertible Debt																			$ 100,000
Convertible Debt																									$ 120,750
Debt Instrument, Face Amount																			115,000
Derivative Liability																			$ 124,666
Debt Instrument, Maturity Date																							Jul. 17, 2016
Debt Discount As Percentage																			10.00%
Percentage Of Lowest Closing Price In 20 Trading Days																			40.00%
Convertible Note Financing On August 19, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Debt Instrument, Unamortized Discount																					$ 54,500		$ 54,500
Debt Instrument, Convertible, Conversion Price																		$ 0.06
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																					5,000,000		5,000,000
Debt Instrument, Face Amount																		$ 66,000
Derivative Liability																		$ 71,548
Debt Instrument, Maturity Date																							Aug. 15, 2015
Debt Discount As Percentage																		10.00%
Proceeds From Convertible Debt Gross																		$ 54,500
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate																		8.00%
Percentage Of Lowest Closing Price In 15 Trading Days																		60.00%
Convertible Note Financing On September 4, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							10.00%
Debt Instrument, Convertible, Conversion Price							$ 0.042
Proceeds from Convertible Debt							$ 100,000
Debt Instrument, Face Amount							110,000
Derivative Liability							119,246
Stock Issued During Period, Value, Conversion of Convertible Securities																					$ 9,195,341
Amortization of Debt Discount (Premium)							$ 10,000														100,000
Percentage Of Lowest Closing Price In 25 Trading Days							60.00%
Convertible Note Financing On September 22, 2014 One [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt																$ 50,000						$ 56,778
Convertible Debt		$ 4,000,000	$ 4,000,000
Debt Instrument, Face Amount		24,772	24,772													$ 54,750
Common Stock Discount Percentage																40.00%
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate																8.00%
Debt Instrument, Unamortized Premium																$ 36,500
Convertible Note Financing On September 22, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt																45,000
Debt Instrument, Face Amount																$ 100,000
Debt Instrument, Maturity Date																							Jun. 19, 2015
Common Stock Discount Percentage																40.00%
Amortization of Debt Discount (Premium)																$ 33,333
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate																8.00%
Debt Instrument, Unamortized Premium																$ 33,333
Debt Conversion, Converted Instrument, Shares Issued																5,210,553
Convertible Note Financing On October 6, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt						$ 50,000
Convertible Debt																					73,641		$ 73,641
Debt Instrument, Face Amount						$ 53,000
Debt Instrument, Maturity Date																							Jun. 1, 2015
Common Stock Discount Percentage						39.00%
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate						8.00%
Debt Instrument, Unamortized Premium						$ 33,885
Convertible Note Financing On October 8, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt					$ 85,500
Convertible Debt Discount					7,500
Stock Issued During Period, Value, Conversion of Convertible Securities																					7,590,186
Debt Instrument, Maturity Date																							Mar. 30, 2015
Legal Fees					$ 7,000
Common Stock Discount Percentage					40.00%
Amortization of Debt Discount (Premium)					$ 66,667
Convertible Note Financing On October 27, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt														$ 33,250
Debt Instrument, Face Amount														36,750
Debt Instrument, Maturity Date																							Oct. 21, 2015
Extinguishment Of Debt Write Off Of Unamortized Debt Discount														$ 14,700
Percentage Of Lowest Closing Price In 20 Trading Days														40.00%
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate														8.00%
Share Price														$ 0.08
Debt Instrument, Unamortized Premium																					24,500		$ 24,500
Debt Instrument, Repurchase Amount																					52,892		$ 52,892
Convertible Note Financing On October 27, 2014 One [Member]
Equity And Debt Financing Agreements [Line Items]
Debt Instrument, Maturity Date																							Oct. 27, 2015
Convertible Note Financing On October 27, 2014 Two [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt														$ 150,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights														1,000,000
Convertible Debt														$ 166,681
Debt Instrument, Face Amount														161,000
Convertible Debt Discount														$ 11,000
Common Stock Discount Percentage														40.00%
Amortization of Debt Discount (Premium)																					107,333
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate														8.00%
Warrants Not Settleable in Cash, Fair Value Disclosure																					33,404		$ 33,404
Convertible Note Financing On October 27, 2014 Two [Member] | Additional [Member]
Equity And Debt Financing Agreements [Line Items]
Convertible Debt														$ 88,319
Convertible Note Financing On December 22, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Reimbursement Expenses For Purchasers Counsel				$ 25,000
Convertible Note Financing On November 25, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Percentage Of Conversion Price Threshold				55.00%
Proceeds from Convertible Debt				$ 3,840,000
Convertible Debt				4,000,000
Debt Instrument, Face Amount				$ 4,000,000
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate				12.00%
Debt Instrument, Periodic Payment				$ 500,000
Reimbursement Expenses For Purchaser				$ 25,000
Percentage Of Conversion Price Of Note Into Common Stock On Closing Price				95.00%
Percentage Of Conversion Price Of Note Into Common Stock				62.50%
Percentage Of Premium On Convertible Note				120.00%
Original Issue Discount Rate				4.00%
Ironridge and Dominion Capital LLC Financing [Member]
Equity And Debt Financing Agreements [Line Items]
Convertible Debt													$ 158,400								4		4
Derivative Liability													571,387								11,230		11,230
Amortization of Debt Discount (Premium)													522,061								48,129,507
Debt, Current													$ 434,592								631,993		631,993
Convertible Note Financing On March 10, 2015 [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt			56,778
Convertible Debt																					54,750		54,750
Debt Instrument, Face Amount		24,772	24,772
Derivative Liability		96,915	96,915																		24,921		$ 24,921
Interest Expense, Debt		30,070
Extinguishment Of Debt Write Off Of Unamortized Debt Discount		$ 24,772
Common Stock Discount Percentage		37.50%
Amortization of Debt Discount (Premium)			$ 81,500																		60,440
Debt Instrument, Convertible, Terms of Conversion Feature			3,560,976
Convertible Note Financing On September 24, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Debt Instrument, Interest Rate, Stated Percentage															8.00%
Proceeds from Convertible Debt															$ 67,750
Debt Instrument, Face Amount															$ 75,000
Stock Issued During Period, Value, Conversion of Convertible Securities																					4,955,411
Amortization of Debt Discount (Premium)																					$ 50,000
Percentage Of Lowest Closing Price In 20 Trading Days															40.00%
Convertible Note Financing On June 30, 2015 [Member]
Equity And Debt Financing Agreements [Line Items]
Debt Instrument, Convertible, Conversion Price																					$ 166,000		$ 166,000
Proceeds from Convertible Debt																							$ 3,540,600
Convertible Debt																					$ 4,293,122		4,293,122
Derivative Liability																					5,258,995		5,258,995
Convertible Debt Discount																					3,153,600		3,153,600	$ 387,000
Stock Issued During Period, Value, Conversion of Convertible Securities																					2,333,333
Amortization, Total																							$ 767,907	27,000
Original Issue Discount Rate																							4.00%
Monthly Funding Amount																					500,000		$ 500,000
Convertible Note Financing On March 4, 2015 [Member]
Equity And Debt Financing Agreements [Line Items]
Debt Instrument, Unamortized Premium																					50,000		50,000
Convertible Note Financing on April 6, 2015 [Member]
Equity And Debt Financing Agreements [Line Items]
Convertible Debt	$ 166,681																				120,750		120,750
Debt Instrument, Face Amount	88,319
Derivative Liability	305,904																				180,152		180,152
Extinguishment Of Debt Write Off Of Unamortized Debt Discount	88,319
Amortization of Debt Discount (Premium)	$ 255,000																				$ 89,889
Debt Conversion, Converted Instrument, Shares Issued																					12,000,000
Debt, Current																					$ 143,075		143,075
First Tranche [Member] | Convertible Note Financing On June 18 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Debt Instrument, Unamortized Discount																				$ 50,000
Debt Instrument, Face Amount																				55,000
Second Tranche [Member] | Convertible Note Financing On June 18 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Debt Instrument, Unamortized Discount																					50,000		50,000
Proceeds from Convertible Debt																							50,000
Debt Instrument, Face Amount																					55,000		55,000
Derivative Liability																					59,623		$ 59,623
Stock Issued During Period, Value, Conversion of Convertible Securities																					6,980,938
Debt Instrument, Maturity Date																							Sep. 19, 2015
First Note [Member] | Convertible Note Financing On September 22, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Debt Instrument, Face Amount																$ 50,000
Second Note [Member] | Convertible Note Financing On September 22, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Debt Instrument, Face Amount																$ 50,000
Third Tranche [Member] | Convertible Note Financing On June 18 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt																							$ 50,000
Convertible Debt																					57,863		57,863
Debt Instrument, Face Amount																					55,000		55,000
Derivative Liability																				62,118	$ 38,378		38,378
Debt Instrument, Maturity Date																					Dec. 22, 2015
Amortization of Debt Discount (Premium)																				$ 50,000			24,295
First Five Tranches [Member] | Convertible Note Financing On June 30, 2015 [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt																							443,400
Eight Tranche [Member] | Convertible Note Financing On June 30, 2015 [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt																							3,650,000	$ 500,000
Eight Tranche [Member] | Convertible Note Financing On June 30, 2015 [Member] | Additional [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt																							150,000
Convertible Note Financings [Member] | Convertible Note Financing On October 27, 2014 Two [Member]
Equity And Debt Financing Agreements [Line Items]
Convertible Debt														$ 4,000,000
Convertible Note Financings [Member] | Convertible Note Financing On June 30, 2015 [Member]
Equity And Debt Financing Agreements [Line Items]
Derivative Liability																					$ 5,739,824		$ 5,739,824
Convertible Note Financings Two [Member] | Convertible Note Financing On March 13, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds From Convertible Debt Gross									$ 75,000

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - Jun. 30, 2015 - $ / shares shares in Thousands	Total
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding - Number Of Options	2,856
Granted - Number Of Options	1,840
Exercised - Number Of Options	0
Forfeited - Number Of Options	0
Outstanding - Number Of Options	4,696
Exercisable - Number Of Options	4,006
Outstanding - Weighted Average Exercise Price	$ 1.26
Granted - Weighted Average Exercise Price	0.01
Exercised - Weighted Average Exercise Price	0
Forfeited - Weighted Average Exercise Price	0
Outstanding - Weighted Average Exercise Price	0.78
Exercisable - Weighted Average Exercise Price	$ 0.91

Stockholders' Deficit (Details

Stockholders' Deficit (Details 1) shares in Thousands	6 Months Ended
	Jun. 30, 2015shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested at beginning of year	200
Issued	0
Vested	(100)
Forfeited	0
Unvested at end of year	100

Stockholders' Deficit (Detail32

Stockholders' Deficit (Details Textual) - USD ($)	Jan. 09, 2015	Sep. 30, 2013	Aug. 26, 2011	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Jan. 08, 2015	Nov. 05, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Total						$ 1,182,000	$ 1,415,000
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number One				3,200,000		3,200,000
Stock Issued During Period, Shares, Share-based Compensation, Gross	150
Percentage Of Closing Stock Price Exceeds Of Conversion Price		400.00%
Series I Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred Stock, Par or Stated Value Per Share		$ 1,000
Preferred Stock, Dividend Rate, Percentage		6.00%
Stock Issued During Period, Shares, Issued for Services		413
Conversion Of Stock Conversion Price	$ 0.027
Preferred Stock, Shares Authorized		0.036
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Date	January 1, 2017
Series I Preferred Stock [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Issued for Services								512
Series I Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 812,500
Preferred Stock, Shares Authorized										2,500	1,000
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Date									January 1, 2017
Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Officers Compensation								$ 200,000
Chief Executive Officer [Member] | Series I Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Issued for Services								100
Stock Issued During Period, Shares, New Issues									381
Board Of Directors And Management [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred Compensation Liability, Current, Total		$ 413,000
Director [Member] | Series I Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Issued for Services								25
Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Issued for Services						6,300,000
Stock Issued During Period Grant date fair Value Issued For Services						$ 147,900
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.06		$ 0.06
Minimum [Member] | Chief Executive Officer [Member] | Series I Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Issued for Services								138
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.75		$ 0.75
Maximum [Member] | Chief Executive Officer [Member] | Series I Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Issued for Services								143
Stock Incentive Plan 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				4,500,000		4,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period			1,000,000
Stock Options and Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Total				$ 200,000	$ 300,000	$ 1,200,000	$ 1,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value						200,000
Board Compensation 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value						$ 187,500
Incentive Compensation 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross	50
Incentive Compensation 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross	475

Income Taxes (Details Textual)

Income Taxes (Details Textual)	1 Months Ended
	Oct. 31, 2012USD ($)	Jun. 30, 2015USD ($)	Mar. 28, 2012USD ($)	Mar. 07, 2012	Dec. 31, 2011USD ($)
Operating Loss Carryforwards [Line Items]
Income Tax Examination, Penalties and Interest Accrued, Total			$ 200,000
Number Of Equal Monthly Payments				24
Outstanding Amount		$ 545,777
Loss Contingency Accrual		345,000
Tax Reassessment [Member]
Operating Loss Carryforwards [Line Items]
Income Tax Examination, Penalties and Interest Expense, Total	$ 950,000
Withholding Tax Assessments [Member]
Operating Loss Carryforwards [Line Items]
Income Tax Examination, Penalties and Interest Expense, Total	$ 220,000
Subsequent Event [Member] | Minimum [Member]
Operating Loss Carryforwards [Line Items]
Income Tax Examination, Penalties and Interest Accrued, Total		$ 140,000
Xmark Corporation [Member]
Operating Loss Carryforwards [Line Items]
Income Tax Examination, Penalties and Interest Accrued, Total					$ 1,400,000

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating Leases, Rent Expense	$ 45,000	$ 61,000
Commitments Amount Funded	110,000	$ 60,000
Other Commitment, Due in Next Twelve Months	$ 230,000
Lease Expiration Date	Oct. 18, 2018
Lease Expiration Period	April 2,015
Debt Instrument, Face Amount	$ 170,000

Employment Contracts and Stoc35

Employment Contracts and Stock Compensation to Related Parties (Details Textual) - USD ($)	Jan. 08, 2013	Sep. 28, 2012	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2011
Related Party Transaction [Line Items]
Stock Compensation To Related Party			$ 68,000	$ 67,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross	738,916
Officer Compensation Payment Description			On January 14, 2014, Mr. Caragols agreement was further amended, lowering his salary to $200,000 per annum through the remaining term of the agreement in exchange for the issuance of 143 shares of Series I Preferred Stock.
Board of Directors Chairman [Member]
Related Party Transaction [Line Items]
Accrued Bonuses, Current					$ 375,000
Bonus Amount Converted For Restricted Stock Shares	$ 300,000
Board of Directors Chairman [Member] | Restricted Stock [Member]
Related Party Transaction [Line Items]
Bonus Amount Converted For Restricted Stock Shares	500,000
Board of Directors Chairman [Member] | Series I Preferred Stock [Member]
Related Party Transaction [Line Items]
Accrued Bonuses, Current	$ 75,000
Board of Directors Chairman [Member] | January 1 2014 [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross			100,000
Board of Directors Chairman [Member] | January 1 2015 One [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross			100,000
Board of Directors Chairman [Member] | January 1 2015 Two [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross			100,000
Board of Directors Chairman [Member] | January 1 2016 One [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross			100,000
Board of Directors Chairman [Member] | January 1 2016 Two [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross			100,000
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Accrued Compensation Expenses		$ 404,423
Officers Compensation		100,000	$ 201,680
Stock Compensation To Related Party Paid In Cash		$ 304,423
Employee-related Liabilities, Current			$ 102,000
Chief Financial Officer [Member] | Restricted Stock [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross		200,000

Agreements with The Boeing Co36

Agreements with The Boeing Company (Details Textual) $ in Millions	12 Months Ended
	Dec. 31, 2013USD ($)	Dec. 31, 2012USD ($)	Jun. 30, 2015USD ($)
License Agreements [Line Items]
Licenses Revenue	$ 2.5	$ 2.5
Number Of License Payment Installments			3
Deferred Revenue			$ 2.5

Subsequent Events (Details Text

Subsequent Events (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Amount	$ 1,781,000	$ 178,000
Debt Conversion, Converted Instrument, Shares Issued	31,086,144
VeriTeQ [Member]
Subsequent Event [Line Items]
Payments to Fund Long-term Loans to Related Parties	$ 15,000
Convertible Notes Payable [Member]
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Amount	$ 367,352